Aquestive Therapeutics (NASDAQ:AQST) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock.

AQST has been the subject of a number of other research reports. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a report on Friday, March 7th. Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. Finally, Lake Street Capital dropped their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $10.57.

Aquestive Therapeutics Trading Up 6.3 %

Aquestive Therapeutics stock opened at $3.04 on Wednesday. Aquestive Therapeutics has a 12-month low of $2.24 and a 12-month high of $5.80. The firm has a market capitalization of $300.57 million, a price-to-earnings ratio of -6.76 and a beta of 2.76. The firm has a 50 day moving average of $2.98 and a 200 day moving average of $3.91.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $13.11 million. On average, analysts predict that Aquestive Therapeutics will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds have recently bought and sold shares of AQST. Intech Investment Management LLC purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $90,000. Charles Schwab Investment Management Inc. raised its position in Aquestive Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock valued at $1,014,000 after purchasing an additional 9,268 shares during the period. Quantbot Technologies LP bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter valued at approximately $135,000. BNP Paribas Financial Markets boosted its holdings in shares of Aquestive Therapeutics by 252.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after purchasing an additional 13,481 shares during the period. Finally, MetLife Investment Management LLC increased its position in shares of Aquestive Therapeutics by 86.3% during the 3rd quarter. MetLife Investment Management LLC now owns 36,096 shares of the company’s stock valued at $180,000 after purchasing an additional 16,716 shares during the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.